Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine-Reference-Cited by-同舟云学术

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine

Published:2017-02-15 Issue:1 Volume:3 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Bayani Jane,Yao Cindy Q.,Quintayo Mary Anne,Yan Fu,Haider Syed,D’Costa Alister,Brookes Cassandra L.,van de Velde Cornelis J. H.,Hasenburg Annette,Kieback Dirk G.,Markopoulos Christos,Dirix Luc,Seynaeve Caroline,Rea Daniel,Boutros Paul C.,Bartlett John M. S.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-016-0003-5.pdf

Reference36 articles.

1. Abe, O. et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).

2. Dowsett, M. et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28, 509–518 (2010).

3. Colleoni, M. et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J. Clin. Oncol. 34, 927–935 (2016).

4. Bartlett, J. et al. Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. Clin. Oncol. (R. Coll. Radiol.). 25, 109–116 (2013).

5. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer;Molecular Cytogenetics;2024-05-04

2. Investigating the Role of SNAI1 and ZEB1 Expression in Prostate Cancer Progression and Immune Modulation of the Tumor Microenvironment;Cancers;2024-04-12

3. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma;Cell Reports;2024-03

4. Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence;Frontiers in Oncology;2023-10-26

5. Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance;Journal of Urology;2023-08